Skip to content

APAF-CSP

AV Nodal Ablation with Conduction System Pacing versus Cardiac Resynchronization for Symptomatic Heart Failure patients with Atrial Fibrillation: The APAF-CSP all-cause mortality and Quality of Life Trial - APAF-CSP Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON61317
Enrollment
64
Registered
2025-12-01
Start date
2026-05-04
Completion date
Unknown
Last updated
2026-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial Fibrillation (AF), Heart Failure (HF) Atrial Fibrillation, Heart Failure

Interventions

All study' subjects meeting the inclusion criteria and not meeting any exclusion criteria will be randomized in a 1:1 ratio to undergo either AV node ablation with CSP or AV node ablation with CRT imp

Sponsors

Universitair Medisch Centrum Groningen
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1- Age 18 years or above. 2- Patient is diagnosed with AF and deemed not amenable for rhythm control. This diagnosis of AF will be demonstrated by at least one Electrocardiographs (ECG) showing AF that were performed within one year prior to enrollment.  3- Has history of stable heart failure (regardless left ventricular ejection fraction) and has a history of at least one HF related hospitalization or emergency room/urgent care visit within 2 years prior to enrollment, despite being on maximally tolerable guideline directed medical therapy. 4-Willing and capable to provide informed consent.

Exclusion criteria

Exclusion criteria: 1-NYHA functional class IV.  2-Severe concomitant non-cardiac disease. 3-Patient who require any cardiac surgical intervention.  4-Previously implanted pacing devices (pacemaker/ICD/CRT) with =40% pacing burden.  5-Any of the following within the 3 months prior to enrollment: myocardial infarction, unstable angina, percutaneous coronary intervention, stroke/TIA, significant bleeding, or pericarditis/effusions. 6- Coronary artery bypass surgery/atriotomy within 6 months prior to enrolment.  7-Women who are pregnant or breastfeeding. 

Design outcomes

Primary

MeasureTime frame
The hierarchical primary composite endpoint is the composite of all-cause mortality, HF hospitalization or unplanned/urgent HF visit, and =5 point improvement (increase) in the Kansas City Cardiomyopathy Questionnaire (KCCQ).

Secondary

MeasureTime frame
-Major secondary endpoint: =5 point improvement (increase) in the Kansas City Cardiomyopathy Questionnaire (KCCQ) score.  - Quality of life improvement (EQ-5D and AFEQT questionnaires).  -HF hospitalization or unplanned/urgent HF visit. -Cardiovascular related hospitalization. -All-cause mortality. -Cardiovascular related mortality.

Countries

France, Germany, Italy, Netherlands

Contacts

Public ContactM Rienstra

Universitair Medisch Centrum Groningen

m.rienstra@umcg.nl+31 50 3611327

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP) · Data processed: Jul 23, 2026